AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Cancer remains one of the leading causes of death globally, with delayed diagnoses and limited access to advanced care significantly contributing to poor outcomes.

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

AstraZeneca has retracted a planned £450 million investment in Britain, citing reduced government support as a key factor.

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...